228 related articles for article (PubMed ID: 27779433)
1. Patient preferences for diabetes treatment attributes and drug classes.
Flood EM; Bell KF; de la Cruz MC; Ginchereau-Sowell FM
Curr Med Res Opin; 2017 Feb; 33(2):261-268. PubMed ID: 27779433
[TBL] [Abstract][Full Text] [Related]
2. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
3. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
Kohsaka S; Takeda M; Kidani Y; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
[TBL] [Abstract][Full Text] [Related]
4. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
Tosaki T; Kamiya H; Yamamoto Y; Himeno T; Kato Y; Kondo M; Yamada Y; Inagaki A; Tsubonaka K; Oshiro C; Katayama T; Hayasaki T; Nakaya Y; Fujiyoshi H; Nakamura J
Intern Med; 2017 Oct; 56(19):2563-2569. PubMed ID: 28883229
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
7. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Hu J; Chen L
Prim Care Diabetes; 2021 Apr; 15(2):227-233. PubMed ID: 32888896
[TBL] [Abstract][Full Text] [Related]
8. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
10. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
11. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial.
Kellett N; West F; Finlay AY
Br J Dermatol; 2006 Mar; 154(3):524-32. PubMed ID: 16445786
[TBL] [Abstract][Full Text] [Related]
12. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
[TBL] [Abstract][Full Text] [Related]
13. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
[TBL] [Abstract][Full Text] [Related]
14. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
15. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
Oita M; Miyoshi H; Ono K; Nakamura A; Cho KY; Nomoto H; Yamamoto K; Omori K; Manda N; Kurihara Y; Aoki S; Atsumi T
Endocr J; 2018 Feb; 65(2):141-150. PubMed ID: 29093280
[TBL] [Abstract][Full Text] [Related]
16. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
17. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
19. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies].
Mühlbacher AC; Kaczynski A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Varying Cost Formats on Preferences.
Jiang CC; Fraenkel L
Med Decis Making; 2017 Jan; 37(1):17-26. PubMed ID: 27856826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]